Rethinking the limits of tissue-agnostic cancer therapy
The promises of a tumour-agnostic oncology are still challenged by conventional clinical trial design and regulatory processes
ctDNA-guided adjuvant chemotherapy in colon cancer: not ready for prime time?
Two studies fail to meet their primary endpoints, reinforcing the need to improve the sensitivity of ctDNA testing before it enters the clinic
Optimising cancer therapy in the era of technological progress
Findings from latest research reflect emerging opportunities in oncology to refine treatments by challenging current paradigms of care
First trial evidence supports minimal residual disease-guided adjuvant immunotherapy in bladder cancer
In the IMvigor011 trial, ctDNA positivity was reported to be strongly predictive of adjuvant immunotherapy benefit in muscle-invasive bladder cancer
Change is on the horizon in the management of uveal melanoma
Novel strategies are offering the possibility of extended patient survival and durable disease control
Novel tissue-agnostic biomarker approaches could improve response to immunotherapy
Several studies describe pan-cancer approaches utilising the latest technology for better patient selection and outcomes
First-line bemarituzumab improves short-term survival in gastric or gastroesophageal junction cancer overexpressing FGFR2b
Positive initial overall survival data were, however, attenuated and may not be clinically meaningful in a longer-term analysis
New artificial intelligence-based biomarkers offer early insight into treatment response
Findings from four studies provide further evidence on the potential of AI-driven pathology, imaging and multiomic data to guide clinical decision-making
Is it time to shift supportive care toward digital-assisted approaches?
Recent findings show digital tools have the potential to improve the monitoring of symptoms and psychological aspects, but they should be integrated within routine clinical practice
Atezolizumab plus a TIGIT inhibitor fails to demonstrate superiority to standard of care in NSCLC
Negative results are reported in SKYSCRAPER-03, while induction immunochemotherapy is investigated as a potential novel approach for unresectable stage II NSCLC